A Pilot Study of Neoadjuvant Nivolumab, Ipilimumab, and Intralesional Oncolytic Virotherapy for HER2-negative Breast Cancer

PURPOSE: Neoadjuvant combination immune checkpoint blockade and intralesional oncolytic virotherapy have the potential to activate antitumor responses in patients with breast cancer. EXPERIMENTAL DESIGN: Eligibility for this pilot phase I trial included patients with localized HER2-negative breast c...

Descripción completa

Detalles Bibliográficos
Autores principales: Nguyen, Vina P., Campbell, Katie M., Nowicki, Theodore S., Elumalai, Nila, Medina, Egmidio, Baselga-Carretero, Ignacio, DiNome, Maggie L., Chang, Helena R., Oseguera, Denise K., Ribas, Antoni, Glaspy, John A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10445661/
https://www.ncbi.nlm.nih.gov/pubmed/37621406
http://dx.doi.org/10.1158/2767-9764.CRC-23-0145

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10445661/
https://www.ncbi.nlm.nih.gov/pubmed/37621406
http://dx.doi.org/10.1158/2767-9764.CRC-23-0145

Ejemplares similares